Immune Reconstitution Inflammatory Syndrome

DR-TB Treatment in Pregnancy: General Considerations

Shorter Injectable-containing MDR/RR-TB Regimen: Pre-treatment evaluation and follow-up​

PTE Objective

Drugs used for the treatment of drug-resistant TB have significant adverse effects. Hence, there is a need for PTE to rule out any underlying condition at the baseline, like co-morbid conditions, radiological abnormalities, Electrocardiogram (ECG) changes, or biochemical derangements. 

PTE is essential to identify:

Pre-treatment Evaluation [PTE] of DR-TB Patients​

The following are the key counselling messages for patients with Tuberculosis (TB):

During the treatment of Drug-resistant TB (DR-TB) patients, there are some important points that patients and caregivers must be counselled on. 

The table below shows all the aspects of DR-TB counselling that must be covered by health workers.

Key Messages for TB Counselling​

 Components of Drug Resistant TB Counselling Tool

Delamanid (Dlm) is considered only for the longer oral Multi (M)/ Extensively Drug-resistant TB (XDR-TB) regimen as per the Programmatic Management of Drug-resistant TB (PMDT) guidelines.

• Formulation: Film-coated tablet with 50 mg Delamanid

​

• Duration:  24 weeks

         The Optimal Background Regimen (OBR) will be continued beyond the 24 weeks of Dlm administration.

​